Literature DB >> 2406998

Area-under-the-curve monitoring of cyclosporine therapy: performance of different assay methods and their target concentrations.

J Grevel1, K L Napoli, S Gibbons, B D Kahan.   

Abstract

The measurement of areas under the concentration-time curve (AUC) was recently introduced as an alternative to trough level monitoring of cyclosporine therapy. The AUC is divided by the oral dosing interval to calculate an average concentration. All measurements are performed at clinical steady state. The initial evaluation of AUC monitoring showed advantages over trough level monitoring with concentrations of cyclosporine measured in serum by the polyclonal radioimmunoassay of Sandoz. This assay technique is no longer available and the following assays were performed in parallel during up to 173 AUC determinations in 51 consecutive renal transplant patients: polyclonal fluorescence polarization immunoassay of Abbott in serum, specific and nonspecific monoclonal radioimmunoassays using 3H and 125I tracers in serum and whole blood, and high performance liquid chromatography in whole blood. Both trough levels and average concentrations at steady state measured by those different techniques were significantly correlated with the oral dose. The best correlation (r2 = 0.54) was shown by average concentrations measured in whole blood by the specific monoclonal radioimmunoassay of Sandoz (3H tracer). This monitoring technique was also associated with the smallest absolute error between repeated observations in the same patient while the oral dose rate remained the same or was changed. Both allegedly specific monoclonal radioimmunoassays (with 3H and 125I tracer) measured significantly higher concentrations than the liquid chromatography. (ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2406998     DOI: 10.1097/00007691-199001000-00003

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  6 in total

Review 1.  Pharmacodynamic monitoring of cyclosporin.

Authors:  W M Awni
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 2.  Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Authors:  J Grevel
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

3.  Prediction of acute graft rejection in renal transplantation: the utility of cyclosporine blood concentrations.

Authors:  J Grevel; K L Napoli; M S Welsh; N E Atkinson; B D Kahan
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

4.  Clinical assessment of trough levels for monitoring of rejection in cyclosporine-treated kidney transplant recipients.

Authors:  S Takahara; M Namiki; Y Kokado; H Kameoka; A Okuyama
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

5.  Chronopharmacokinetics of Cyclosporine A in the Wistar rat following oral administration.

Authors:  M F Malmary; K Kabbaj; C Labat; A Batalla; I Houti; S Moussamih; J Oustrin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441

Review 6.  A review of assay methods for cyclosporin. Clinical implications.

Authors:  K T Kivistö
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.